Copaxone pricing boosts Teva earnings; Valeant posts $973M loss on charges;

@FiercePharma: Biggest report yesterday: Top 10 Drug Patent Losses of 2014. Feature | Follow @FiercePharma

@CarlyHFierce: Teva CEO Jeremy Levin steps down amid board squabble. Top story yesterday via FiercePharma | Follow @CarlyHFierce

> Teva Pharmaceutical Industries ($TEVA) posted better-than-expected earnings, but shares still fell on investor worries about CEO Jeremy Levin's departure. Report

> Valeant Pharmaceuticals ($VRX) reported a quarterly net loss of $973 million, which it blamed on restructuring costs and impairment charges. Report

> Adcock Ingram's largest shareholder remains undecided about Chilean drugmaker CFR Pharmaceuticals' $1.3 billion takeover offer. Report

> Denmark's Lundbeck said it expanded its partnership with Japan-based Otsuka to cover its drug for alcoholism in Japan. Report

> Hungary's Richter hiked its 2013 sales outlook on strong sales prospects in Hungary and Romania. Report

Medical Device News

@FierceMedDev: Veracyte goes public, raises $65M and gains on Day 1. Article | Follow @FierceMedDev

@MarkHFierce: Carlos Slim backs more genomics and Dx work at the Broad Institute, and elsewhere, with a new infusion of $74M. FierceDiagnostics story | Follow @MarkHFierce

@MichaelGFierce:  | Follow @MichaelGFierce

> HeartMate pump propels Thoratec revenue. More

> Elixir's dissolving stent aces 12-month study as Abbott duel looms. Story

> Abbott, Cordis-backed study challenges stent options for coronary bifurcation lesions. Item

Biotech News

@FierceBiotech: Parexel's stock plunges despite spikes in revenue, profit. Report from FierceCRO | Follow @FierceBiotech

@JohnCFierce: Feds launch probe of AstraZeneca's controversial late-stage Brilinta study. Article | Follow @JohnCFierce

@DamianFierce: Do-it-all CRO inVentiv is buying Catalina Health to boost its patient adherence business. News | Follow @DamianFierce

@EmilyMFierce: New survey details impact of federal cuts, sequestration on scientific research. FierceBiotech Research story | Follow @EmilyMFierce

> Roche looks to trump GLP-1 diabetes drugs with a combo approach. More

> Ariad shares plunge again after FDA asks for a halt to Iclusig sales. Story

> Alzheimer's experts team up with Adimab, grab $10M to launch Alector. News

Pharma Manufacturing News

@EricPFierce: Manufacturing, sanitation issues at Sanofi's Toronto vaccine plant has been a problem for some time now. Story | Follow @EricPFierce

> Foreign cancer-drug dealer gets prison. More

> Space issues lead GSK to close NJ facility, shift production. Report

> DSM opens Australia biologics plant. Story

> India renews duty on Chinese paracetamol. Article

Vaccines News

> Sanofi makes case for Fluzone superior clinical benefit label. News

> GSK, Sanofi join Gates Foundation vaccine R&D initiative. Report

> Vaccines a rare bright spot in Merck's gloomy financials. More

> ACIP recommendation gives Novartis a new growth opportunity. Story

> Dendreon reportedly seeking buyer for struggling business. Article

And Finally... The FDA found that about 12% of spices imported to the U.S. are contaminated. Report

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.